All In Biotech

Drug Trial Radar · NCT05059262

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

123

Actual

Start

Oct 14, 2021

Primary completion

Aug 10, 2023

Study completion Jul 2028

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.

Conditions

  • Tenosynovial Giant Cell Tumor
  • Pigmented Villonodular Synovitis
  • Giant Cell Tumor of Tendon Sheath
  • Tenosynovial Giant Cell Tumor, Diffuse
  • Tenosynovial Giant Cell Tumor, Localized

Interventions

  • VimseltinibDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1Time frame: Baseline to Week 25 (Cycle 7, Day 1)

Locations

35 sites in 13 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • University of Colorado

    Aurora, Colorado

  • University of Kansas

    Kansas City, Kansas

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke Sarcoma Research

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • McGill University

    Montreal, Canada

  • Princess Margaret Hospital

    Toronto, Canada

  • Institut Bergonié

    Bordeaux, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • Helios Klinikum Berlin-Buch

    Berlin, Germany

  • University Hospital Essen (Universitätsklinikum Essen)

    Essen, Germany

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

  • Istituto Ortopedico Rizzoli

    Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • Istituto Oncologico Veneto

    Padua, Italy

  • Istituto Nazionale Tumori Regina Elena

    Rome, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Oslo University Hospital

    Oslo, Norway

  • Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

    Warsaw, Poland

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Universitäts-Kinderspital beider Basel (UKBB)

    Basel, Switzerland

  • Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust

    London, United Kingdom

  • University College London Hospitals

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.